Nasdaq Transition Greenbrook recently delisted from Nasdaq due to stock price and equity requirements, signaling a potential need for cost-effective, scalable technology and operations solutions to optimize liquidity, reporting, and regulatory compliance across multi-state clinical sites.

Debt Financing The company has been actively securing debt financing in 2024, including new senior secured term loans, indicating readiness for capital investments. This presents a sales opportunity for financial, IT, or operations solutions that enable rapid deployment of expanded services or facility upgrades.

Growth Platform With multiple TMS and esketamine offerings and nationwide locations, Greenbrook is scaling evidence-based treatments. There is potential for partnerships in patient engagement platforms, telehealth integration, clinician training tools, and centralized data analytics to support expansion.

Leadership Expansion Recent appointments of a Chief Financial Officer and independent board member suggest strategic governance and financial discipline. This creates openings for strategic advisory services, ERP/finance-tech implementations, and vendor-management optimization.

Tech Stack Modernization Current technologies include standard corporate tools and web assets; opportunities exist to modernize cybersecurity, data integration, patient CRM, and marketing tech (e.g., analytics, SEO, digital patient acquisition) to improve reach and conversion across locations.